Stephen C Mercer

US Patent:

7384930, Jun 10, 2008

Filed:

Oct 11, 2005

Appl. No.:

11/247697

Inventors:

Prasad V. Chaturvedula - Cheshire CT, US
Stephen E. Mercer - Middletown CT, US
Haiquan Fang - Madison CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
C07D 401/14
C07D 519/00
A61P 25/06
A61K 31/55

US Classification:

51421206, 540521

Abstract:

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

US Patent:

7384931, Jun 10, 2008

Filed:

May 3, 2006

Appl. No.:

11/417326

Inventors:

Prasad V. Chaturvedula - Cheshire CT, US
Stephen E. Mercer - Middletown CT, US
Haiquan Fang - Madison CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
C07D 401/14
C07D 519/00
A61K 31/55
A61P 25/06

US Classification:

51421206, 540521

Abstract:

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

US Patent:

7470679, Dec 30, 2008

Filed:

May 1, 2007

Appl. No.:

11/742615

Inventors:

Stephen E. Mercer - Middletown CT, US
Prasad V. Chaturvedula - Cheshire CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
C07D 401/14
C07D 519/00
A61K 31/55
A61P 25/06

US Classification:

51421206, 540521

Abstract:

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

US Patent:

7470680, Dec 30, 2008

Filed:

May 1, 2007

Appl. No.:

11/742626

Inventors:

Prasad V. Chaturvedula - Cheshire CT, US
Stephen E. Mercer - Middletown CT, US
Haiquan Fang - Madison CT, US
Xiaojun Han - Cheshire CT, US
Guanglin Luo - Madison CT, US
Gene M. Dubowchik - Middlefield CT, US
Graham S. Poindexter - Old Saybrook CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
C07D 401/14
C07D 519/00
A61K 31/55
A61P 25/06

US Classification:

51421206, 540521

Abstract:

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

US Patent:

7544680, Jun 9, 2009

Filed:

Apr 18, 2008

Appl. No.:

12/105434

Inventors:

Prasad V. Chaturvedula - Cheshire CT, US
Stephen E. Mercer - Middletown CT, US
Haiquan Fang - Madison CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/00
C07D 491/00
A61K 31/55
A61P 25/06

US Classification:

51421207, 540523

Abstract:

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

US Patent:

7772244, Aug 10, 2010

Filed:

Mar 28, 2005

Appl. No.:

11/091429

Inventors:

Andrew P. Degnan - New Haven CT, US
Xiaojun Han - Cheshire CT, US
Gene M. Dubowchik - Middlefield CT, US
John E. Macor - Guilford CT, US
Stephen E. Mercer - Middletown CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/517
A61K 31/47
C07D 215/227
C07D 239/80

US Classification:

51426622, 514312, 544286, 546157

Abstract:

The present invention relates to compounds of Formula (I).

US Patent:

20180161356, Jun 14, 2018

Filed:

Feb 4, 2016

Appl. No.:

15/549021

Inventors:

- Princeton NJ, US
- Horsholm, DK
Peter Hagedorn - Hørsholm, DK
Anja Mølhart Høg - Hillerød, DK
Marianne Lerbech Jensen - Koge, DK
Niels Fisker Nielsen - Kgs. Lyngby, DK
Dong Li - Wallingford CT, US
Jeffrey M. Brown - Medway MA, US
Stephen E. Mercer - Wallingford CT, US

International Classification:

A61K 31/712
A61P 25/28

Abstract:

The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

US Patent:

20170182050, Jun 29, 2017

Filed:

Apr 1, 2015

Appl. No.:

15/300602

Inventors:

- Princeton NJ, US
Stephen E. Mercer - Middletown CT, US
Richard E. Olson - Orange CT, US
Xiaoliang Zhou - Guilford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/517
C07D 403/12

Abstract:

The compound N2-(3-(difluoromethoxy)-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N4,5,5-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine: [PLEASE INSERT CHEMICAL STRUCTURE HERE] reduces -amyloid peptide (A 42) production and has low potential for bioactivation, and may be useful in the treatment of Alzheimer's Disease and other conditions affected by -amyloid peptide (A 42) production.